4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration

Loading news article.

4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration | WAPE

4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration

Article summary

Related companies

Comments —